The loss of myocardial mass can result in ventricular remodeling that is known to affect patient prognosis (20, 26) . Several studies have attempted to identify the mechanism for the progression from myocardial infarction to end-stage heart failure (1, 8, 24) . However, the critical events that lead to the progressive deterioration of left ventricular function are unknown.
Apoptosis is a mechanism of cell death that differs significantly from necrosis in morphological characteristics, regulation, and potential for pharmacological manipulation (19) . Recently, many studies have demonstrated the occurrence of apoptosis during or after myocardial infarction (6) , end-stage heart failure (22, 23) , and acute ischemia-reperfusion (12) as well as in hypoperfused hibernating myocardium (5) . Although it is speculated that myocyte apoptosis is likely involved in the progression of end-stage heart failure (22) , apoptosis in patients with less severe heart failure has not been extensively examined. Furthermore, little is known about the signals that induce and/or modulate myocardial apoptosis. If apoptosis does indeed contribute to the pathophysiology of cardiomyopathy, the therapeutic manipulation of these signals will comprise an important future strategy to delay or prevent disease progression (7) .
The receptor FAS is a type I membrane receptor protein and a member of the tumor necrosis factor receptor superfamily (17) . FAS is expressed by a variety of cells including T cells, hepatocytes, keratinocytes, and other cell types of the thymus, lung, and ovary (11, 16, 28) . In cells that express FAS and downstream components of FAS signal transduction, activation of the receptor by the FAS ligand or by activating antibodies to FAS can induce apoptosis in vitro and in vivo (13, 20) . Although the expression of FAS by the myocardium in vivo has not been extensively investigated, recent studies in vitro have demonstrated induction of FAS expression in cultured neonatal rat cardiomyocytes by exposure to hypoxia (31) .
In both the rat and human heart (6, 25) , apoptosis has been observed in viable myocytes that remain after myocardial infarction. Recent examinations of dogs with chronic heart failure (30) have found myocyte apoptosis in regions immediately adjacent to fibrous scars or old infarcts. For these reasons, we hypothesized that the induction of apoptosis in analogous regions of the human heart might be facilitated by the expression of FAS by the cardiomyocytes or other supporting cells within those regions. We report here the finding of FAS expression adjacent to fibrotic foci and its relationship to DNA end labeling in biopsies of failing human heart.
MATERIALS AND METHODS
Tissue samples. Human heart tissue was obtained during coronary artery bypass grafting (CABG) performed on individuals with coronary artery disease who required this procedure as part of their treatment at Evangelismos General Hospital, Athens, Greece. Patients who were undergoing CABG and had left ventricular systolic dysfunction were selected for the study. Biopsies were obtained from the left ventricle of seven male patients. The sample was taken during the operation while the patient was on extracorporeal circulation; the site of the biopsy was near the apex in an area far from the site of a visible scar. A small sphenoid biopsy was excised, and the incision was closed with a single suture. All tissues were immediately cooled to 4°C and within 5 min were fixed in 10% neutral buffered Formalin. The fixed tissues were embedded in paraffin and sectioned at 5-µm thickness. All tissue samples were coded, and clinical data of the patients were not made available until after the study. The sampling protocol was approved by the Ethical Committee and the Scientific Board of Evangelismos General Hospital, and informed consent was obtained from all patients.
In situ end labeling. Tissue sections were deparaffinized by passing through three changes of xylene, then xylene-alcohol (1:1) for 15 min and 100% ethanol and 70% ethanol for 10 min each. In situ end labeling (ISEL) of fragmented DNA was performed by a modification of the method of Wijsman et al. (35) . Briefly, the samples were incubated with 3% hydrogen peroxide to block endogenous peroxidase activity and then with proteinase K to permit access of reagents to intracellular DNA. The samples were then incubated for 2 h at 18°C in ISEL solution (0.001 mM digoxigenin-11-dUTP, 20 U/ml DNA polymerase I, and 0.01 mM each of dATP, dCTP, and dGTP). Afterward, the heart sections were treated with antidigoxigenin alkaline phosphatase, which was detected with a Fast Blue chromogen system. ISEL-positive cells were quantitated by locating the same region of tissue on three adjacent tissue sections prepared by ISEL, FAS labeling, and hematoxylin and eosin. FAS-positive and FAS-negative regions were located, and total nuclei within each region were scored by hematoxylin staining. The same region was located on the ISEL-labeled section, and ISEL-positive nuclei were then scored. A minimum of 150 nuclei were quantitated in FAS-positive and FAS-negative regions in 3 separate heart sections. The compiled data are reported as means Ϯ SD.
Immunohistochemistry. For detection of FAS, deparaffinized heart sections were incubated with 1% BSA in PBS to block nonspecific binding. The sections were then incubated for 24 h at 4°C with monoclonal anti-human FAS (clone CH-11, Upstate Biotechnology, Saranec Lake, NY) at 1:200 dilution in PBS containing 1% BSA. Secondary antibody (biotinylated anti-mouse IgM) was applied for 2 h at 37°C in a humidified chamber; the diluent was 1% BSA in PBS containing 2 µg/ml DNase-free ribonuclease (RNase, Boehringer Mannheim, Indianapolis, IN). The biotinylated secondary antibody was detected with ABC detection system (Vector Laboratories, Burlingame, CA) and diaminobenzidine. The stained sections were mounted in Fluoromount solution (Southern Biotechnology, Birmingham, AL) containing 0.5 µg/ml propidium iodide (Sigma, St. Louis, MO) for fluorescence detection of chromatin.
Collagen detection and microscopy. Collagen was detected under polarized light on heart sections prepared by the Picrosirius red technique performed as previously described (10) . Hematoxylin and eosin staining was performed by standard protocols. Photomicroscopy was performed with an Olympus BH2 fluorescence/phase-contrast microscope fitted with the PM10ADS automatic photography system. Propidium iodide fluorescence was detected under epifluorescence illumination with 475-to 510-nm excitation filter and Ͼ590-nm emission filter.
RESULTS

Patients.
Clinical data of the patients are shown in Table 1 . All patients with the exception of patient 2 had angina before operation. Patient 2 suffered an acute inferior myocardial infarction and acute mitral regurgitation due to rupture of chordae tendinae and was operated on 10 days after the acute event. All patients except patient 3 had previously documented myocardial infarction; all but patient 5 were hypertensive. As discussed further below, no clear relationship was observed between the clinical data and the degree of labeling by ISEL, FAS immunohistochemistry, or Picrosirius red procedures individually; however, a spatial association between two of the labels was found in all patient samples. Depending on location within the biopsy, samples exhibited varying numbers of leukocytes (data not shown), scarring, and regions devoid of nuclei.
ISEL of the myocardium. All samples were subjected to ISEL of fragmented DNA to identify cells undergoing apoptosis or DNA repair (Fig. 1 ). Cells were scored as apoptotic if the nucleus was ISEL positive (blue) and also displayed chromatin condensation against nuclear envelop and/or nuclear fragmentation (Fig. 1B , arrows denote representative examples). ISEL-positive nuclei were observed in all samples without apparent association to clinical findings (data not shown). In agreement with earlier studies, isolated regions of heavy ISEL were observed in some samples, usually near scars detected by Picrosirius red (see below). No ISEL was observed in regions of myocardium devoid of nuclei (data not shown), nor in control samples prepared without biotinylated dUTP (Fig. 1D) .
Fibrosis and nuclear morphology. Collagen was detected as yellow-white color when viewed under polarized light in samples prepared by the Picrosirius red technique (10) . Collagen was found in perivascular fibrotic foci (Fig. 1, E and F http://ajpheart.physiology.org/ myocardium and in and around isolated scars ( Fig. 2A) . Fibrosis was detected in all patient samples, albeit to varying degrees.
Labeling of the myocardium with the nucleic acid intercalating agent propidium iodide, after exhaustive treatment with DNase-free ribonuclease, permitted clear evaluation of nuclear and chromatin morphology within the myocardium (Fig. 2, B and C) . Along the borders of scars, remaining viable nuclei (Fig. 2B , right) contained normal nuclear morphologies that were generally free of condensed chromatin or nuclear fragmentation. This is in contrast to the nuclear remnants or enucleated regions within the scar (Fig. 2B, left, same region of fibrosis as that in Fig. 2A, left) . At higher magnification (Fig. 2C) , occasional cells along the border itself exhibited nuclear fragmentation and chromatin condensation typical of apoptosis (arrowhead).
Immunohistochemistry for FAS. Monoclonal antibody CH-11 raised against human FAS antigen labeled both large and small isolated regions of myocardium (Fig. 3, A and B) . When the same region of tissue was localized in serial sections prepared simultaneously for evaluation of histology, fibrosis, and FAS (Fig. 4) , the expression of FAS was found to occur adjacent to the fibrotic foci. This relationship held regardless of whether the fibrosis was perivascular (Fig. 4, B and C, left) or http://ajpheart.physiology.org/ whether it was associated with a larger area of scar distal to vessels (Fig. 4, B and C, right) . Simultaneous FAS and propidium iodide labeling of the same tissue section indicated that immunoreactivity to the anti-FAS monoclonal antibody (Figs. 5A, bottom) was detectable on viable heart cells adjacent to fibrosis (compare with Fig. 5B, bottom) , but not within the fibrotic focus (Fig. 5, A and B, top) .
In many areas of the myocardium that labeled positively with anti-FAS antibodies, cell nuclei also became labeled with the ISEL technique (Fig. 6) , consistent with induction of apoptosis in cells expressing FAS. However, quantitation of ISEL-positive nuclei in regions that were FAS positive (see solid rectangle in Fig.  6 , A and C) revealed an ISEL-labeling index (67.6 Ϯ 5.8% of total nuclei) that was not different from that of FAS-negative regions (69.5 Ϯ 9.8% ISEL positive).
DISCUSSION
The results of ISEL studies confirm that DNA fragmentation is present in patients with systolic dysfunction. Our results are comparable to those of Narula et al. (22) and Olivetti et al. (25) , who found Ͼ5% and Ͻ1%, respectively, of apoptotic myocytes in patients with heart failure or with myocardial infarction. In contrast, our ISEL data found fragmented DNA in 60-70% of total nuclei. As discussed by Grasl-Kraup et al. (13) , DNA labeling techniques such as ISEL and terminal deoxynucleotidyl transferase-mediated nick end labeling do not discriminate between apoptotic, necrotic, or autolytic cells, and thus the number of cells actually undergoing apoptosis is likely much less than that suggested by the ISEL data. Although the numbers of apoptotic cells detected in these studies differ, the methods of detection and scoring clearly differed; in addition, differences in the hemodynamic, hypoxic, or other signals that may trigger apoptosis in the heart, as well as the timing and location of biopsy in relation to these signals, all could account for disparities in the percentage of apoptotic cells observed by various research groups.
Regardless, the occurrence of apoptosis within cells of any type comprising the heart parenchyma may have an important impact on the remodeling of the left ventricle. Apoptosis is believed to play an important role in myocardial cell death in the acute phase of myocardial infarction, not only near the infarct but also in remote areas (18, 25) . However, no data exist to indicate whether this situation persists chronically. Interestingly, the biopsy that displayed the greatest percentage of ISEL-labeled nuclei was from the single patient (patient 2) who was biopsied within days, rather than years, after infarction (Table 1 ). Whether or not the incidence of apoptosis is related to time from myocardial infarction is not clear but will constitute an interesting topic for future study. Although our data suggest that apoptosis persists for many years postinfarction in patients with systolic dysfunction, it is unknown if apoptosis persists in myocardial infarction patients with small infarcts without systolic dysfunction. After infarction, the surviving portion of the left ventricle undergoes a lengthening with a secondary volume overload and progressive hypertrophy (26) . Wall thinning and myocyte hypertrophy are greater near the infarcted tissue (2) . Cell loss, myocardial fibrosis, myocyte lengthening, and slippage of cells all participate in the compensation of the heart in this setting (4) . In ischemic cardiomyopathy, fibrotic foci are found with or without a healed infarct; these foci can include scarring from previous infarcts, perivascular/ interstitial fibrosis, as well as microscopic fibrotic foci remote from the area of the infarction (4). In the present study, expression of FAS was observed in association with perivascular fibrosis and with fibrous scars. Although individual microscopic foci of fibrosis were not observed in association with microscopic foci of FAS expression, it is possible that such an association exists but was difficult to discriminate in large or diffuse regions of FAS expression. Regardless, our finding of FAS expression adjacent to either perivascular fibrosis or adjacent to scars suggests that a common mechanism may underlie the association. With regard to noncardiac cell types, the role of extracellular matrix components in the regulation of cell death is being investigated actively (3, 15) . Although the influence of extracellular matrix components on myocyte death is largely unknown, it seems reasonable to speculate that direct interaction of myocytes with the altered extracellular matrix of fibrotic foci may act to modulate or induce FAS expression and/or the subsequent susceptibility of myocytes to apoptotic signals.
Circulating and tissue hormones and/or hemodynamic overload may trigger fibroblast proliferation and accumulation of collagens in the absence of cell loss (9, 25, 34) . On the other hand, death of individual myocytes occurs in ischemic heart disease and leads to the formation of foci of ''replacement fibrosis''; recently, an increased collagen accumulation has been described in the left and right ventricle of patients with ischemic cardiomyopathy (29) . Interestingly, the in vitro studies of Tanaka et al. (31) have shown that embryonic cardiomyocytes in culture begin to express FAS after exposure to hypoxia. It is not yet known if hypoxia also induces FAS expression in the adult human myocardium; however, cells adjacent to or overlying fibrotic foci might reasonably be expected to become hypoxic if Fig. 3 . Immunoreactivity of failing human myocardium to anti-FAS antibodies. Biopsies were immunostained with monoclonal antibodies to human FAS (clone CH-11) and were treated simultaneously with DNase-free RNase and propidium iodide (32) . A: regions of intense reactivity and small isolated foci were found in all samples; positive reactivity is black by diaminobenzidine reaction (arrows). Biopsy shown is from patient 7; note vessels within regions of intense reactivity (bottom right). B: larger diffuse foci of immunoreactivity also were observed without apparent associations with vessels. Bar ϭ 200 µm. Our observations are consistent with this hypothesis; variable numbers of leukocytes were observed in all patient samples (data not shown). In addition, some parenchymal cells that expressed FAS were found to label also by the ISEL technique (Fig. 6) , suggesting that at least some of the cells expressing FAS also were undergoing apoptosis. On the other hand, regions of the parenchyma that were positive for FAS but negative for ISEL also were observed. Furthermore, quantitation revealed that ISEL-positive nuclei were present in the same abundance within regions that were FAS negative as in those that were FAS positive (see RESULTS). The latter results suggest that other initiators of apoptosis may be equally if not more important than FAS in the failing heart. This interpretation assumes that the expression of FAS is maintained by cells throughout the later stages of apoptosis that are detected by techniques such as ISEL. Whether or not this assumption is correct will require kinetic studies of both FAS expression and DNA end labeling in isolated heart cells.
Regardless, these observations are consistent with the notion that expression of FAS by myocardial cells in itself is not sufficient to induce apoptosis but may render cells ''competent'' for induction of the death pathway pending contact with activators of the receptor and/or other stimuli. A confirmation of this hypothesis may be possible by careful sequential studies of an animal model of heart failure supplemented with exogenously administered ligators of FAS. The feasibility of such an approach is supported by the recent demonstration that intratracheal administration of anti-FAS antibodies induced lung epithelial cell apoptosis and pulmonary fibrosis in mice (14) .
In summary, our study of biopsies of failing human heart found that FAS was expressed by remaining heart cells adjacent to fibrotic foci but not in areas distal to fibrosis. We observed the same pattern associ- http://ajpheart.physiology.org/ ated with fibrosis near (perivascular) or far from vessels and in all patient samples. We speculate that expansion of fibrosis in the failing heart may be accelerated through induction of myocardial FAS expression, subsequent activation of apoptosis, further loss of parenchymal cells, and more fibrosis, leading to a vicious cycle and continuous deterioration of ventricular function.
